INTRODUCTION
============

Metabolic syndrome represents a cluster of cardiometabolic risk factors, including central obesity, elevated blood pressure, impaired glucose metabolism, and atherogenic dyslipidemia. The prevalence of metabolic syndrome is currently reaching epidemic proportions throughout the world. Subjects with metabolic syndrome are more susceptible to type 2 diabetes,[@B1] cardiovascular disease (CVD),[@B1] and some cancers,[@B2] which are major leading causes of death, especially in developed countries.

*Panax ginseng* has been used to promote general health and treat illness in traditional oriental medicine. Particularly, Korean red ginseng (KRG) has been reported to have various beneficial effects on vascular health, energy metabolism, pain-relief, and cancer prevention.[@B3] Many animal studies have shown that KRG has potential benefits on cardiovascular disease and several metabolic parameters,[@B4]-[@B8] but human studies have not provided consistent evidence yet.[@B9]-[@B14] Moreover, although most human studies have been conducted in patients with individual diseases, such as hypertension, diabetes, and hyperlipidemia, little is known about the effects of KRG on cardiovascular risks in subjects with metabolic syndrome.

The aim of this double-blind, placebo-controlled, randomized study was to investigate the effects of KRG on cardiovascular risks in subjects with metabolic syndrome, including blood pressure, fasting plasma glucose, insulin sensitivity, lipid profile, oxidized low density lipoprotein (LDL) level, and arterial stiffness.

METHODS
=======

1. Study Subjects
-----------------

A single-center, double-blind, placebo-controlled, randomized clinical trial was designed. The study was approved by the institutional review board (IRB) of Gangnam Severance Hospital, Yonsei University College of Medicine in Seoul, Korea (IRB no. 3-2009-0015). The study complied with the code of ethics of the World Medical Association (Declaration of Helsinki) with all subjects giving informed consent before participation.

Study subjects were older than 20 years of age, presented with metabolic syndrome, and were recruited by advertisement from August 2009 to December 2010. The modified National Cholesterol Education Program Adult Treatment Panel III was used for the definition of metabolic syndrome.[@B15] Metabolic syndrome was defined by the presence of 3 or more of the following risk factors: 1) waist circumference ≥ 90 cm for men and ≥ 80 cm for women, 2) high triglyceride ≥ 150 mg/dL, 3) low high density lipoprotein (HDL) cholesterol \< 40 mg/dL for men and \< 50 mg/dL for women, 4) elevated systolic blood pressure ≥ 130 mm Hg or elevated diastolic blood pressure ≥ 85 mm Hg, and 5) high fasting plasma glucose ≥ 100 mg/dL based on the revised American Diabetes Association criteria.[@B16] Subjects were excluded if they were taking drugs that could affect metabolic and vascular functions, including blood pressure-lowering drugs, anti-diabetic drugs, and lipid-lowering drugs, had uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg), fasting blood sugar ≥ 126 mg/dL, hyperlipidemia (triglycerides ≥ 400 mg/dL or total cholesterol ≥ 250 mg/dL), or a history of cardiovascular disease. After the initial screening visit, subjects were randomly assigned in a double-blind fashion to receive either 1.5 g of KRG (KRG powder capsule; Korea Ginseng Co., Seoul, Korea) or identical-appearing placebo with ginseng flavor three times a day for 12 weeks. Randomization was done according to computer-generated random number sequence. KRG was prepared from roots of a 6-year-old fresh *Panax ginseng* C.A. Meyer, which were harvested in Korea. Red ginseng was made by steaming fresh ginseng at 90℃ to 100℃ for 3 hours and then drying at 50℃ to 80℃. A voucher specimen was deposited at the Korea Ginseng Corporation. KRG was analyzed by high-performance liquid chromatography. KRG contained major ginsenoside-Rg1: 2.89%, Re: 2.16%, Rf: 0.93%, Rh1: 0.13%, Rg2: 0.58%, Rb1: 5.16%, Rc: 2.22%, Rb2: 1.82%, Rd: 0.47%, Rg3: 0.22%, and other minor ginsenosides.

2. Measurements
---------------

We collected anthropometric measurements, blood for laboratory testing, and brachial-ankle pulse wave velocity (baPWV) at the initial (week 0) and final (week 12) visits ([Figure 1](#F1){ref-type="fig"}). Past medical history, health-related behaviors (smoking, alcohol intake, and regular exercise), and anthropometric measurements were obtained through a structured history review and a physical examination. Body weight and height were measured while the subject was wearing light indoor clothing without shoes and were rounded to the nearest 0.1 kg and 0.1 cm, respectively. Body mass index was calculated as the ratio of weight (kg)/height (m^2^). Blood pressure was measured in the right arm using a standard mercury sphygmomanometer (Baumanometer; WA Baum Co., Copiague, NY, USA). After a 12-hour overnight fast, blood samples were obtained from the antecubital veins. Specimens were centrifuged, and the serum was immediately frozen at -80℃. Leukocyte counts were quantified by an automated blood cell counter (ADVIA 120; Bayer, Tarrytown, NY, USA). Serum levels of blood glucose, insulin, high-sensitivity C-reactive protein (CRP), total cholesterol, HDL-cholesterol, and triglyceride were assayed enzymatically (Bayer) using an ADVIA 1650 auto-analyzer (Bayer). Insulin resistance was estimated using the homeostatic model assessment of insulin resistance (HOMA-IR) with the following equation: HOMA-IR = (fasting insulin \[µIU/mL\] × fasting plasma glucose \[mg/dL\]/405). Oxidized LDL-cholesterol was measured using an electrochemiluminescence immunoassay with the Mercodia Oxidized LDL Competitive ELISA test (Mercodia, Uppsala, Sweden), a solid-phase enzyme immunoassay modified from the original method of Holvoet et al.[@B17] During incubation, oxidized LDL in the sample competes with a fixed amount of oxidized LDL bound to the microtiter wells for binding of biotin-labeled specific antibodies (mAb-4E6).

Arterial stiffness was measured via baPWV using a volume-plethysmographic apparatus (PWV/ABI; Colin Co., Komaki, Japan). The coefficients of variation were 8.4% for interobserver reproducibility and 10.0% for intraobserver reproducibility.

3. Sample Size Estimation
-------------------------

The intended sample of 60 recruited subjects provided a power of approximately 80%, assuming a significance level \< 0.05, to detect a 9.5 mm Hg placebo-adjusted treatment effect in systolic blood pressure (change from baseline to week 12) with a standard deviation of 11.5 mm Hg. The drop-out rate was expected to be less than 20%, based on the documented good tolerability of nutraceutical combination. The formula for the sample size was as follows: n = 2(z~α/2~ + z~β~)^2^ / {(µ~0~ - µ~1~) / σ}^2^; α = 0.05, β = 0.20, two population means (µ~0~ and µ~1~), σ^2^ = common variance.

4. Statistical Analysis
-----------------------

Data are presented as mean ± SD. The primary outcome (blood pressure and arterial stiffness) and the secondary outcome (metabolic and inflammatory markers) were used to compare the KRG group to the placebo group. The Wilcoxon signed-rank test was used to calculate the significances of the differences from baseline in each group. The effects of treatment relative to the control levels were analyzed by comparing the changes from baseline between the two treatment arms using Wilcoxon rank-sum test. All analyses were conducted using SAS ver. 9.1 (SAS Inc., Cary, NC, USA). All statistical tests were two-sided, and a P \< 0.05 was considered significant.

RESULTS
=======

The study criteria were met by 60 subjects who were randomized for participation. We defined good compliance as taking more than 80% of the pills given to the participants. Of these, 12 subjects withdrew (11 due to noncompliance and 1 due to time conflicts) and 48 subjects completed the study (KRG group, n = 23; placebo group, n = 25) ([Figure 1](#F1){ref-type="fig"}). According to the self-reported questionnaire, one subject reported gastrointestinal disturbance after placebo administration, whereas there were no reported adverse reactions to KRG administration.

Baseline characteristics of all subjects are presented in [Table 1](#T1){ref-type="table"}. The following parameters were similar in both the KRG and placebo group: age, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, total cholesterol, HDL-cholesterol, triglyceride, insulin, oxidized LDL, CRP, leukocyte count, and baPWV. [Table 2](#T2){ref-type="table"} summarizes the inter- and intra-group differences in metabolic parameters, arterial stiffness, and inflammatory markers. Mean waist circumference and systolic blood pressure decreased significantly in the KRG group (P = 0.015 and P = 0.038, respectively) and mean HDL-cholesterol increased in the KRG group (P = 0.019). Mean systolic blood pressure and diastolic blood pressure decreased in the placebo group (P \< 0.001 and P \< 0.001, respectively). However, the extent of change in waist circumference, blood pressure, and HDL-cholesterol between the KRG and placebo groups was not significantly different. Oral administration of KRG did not significantly affect blood pressure; inflammatory markers, including oxidized LDL, CRP, and leukocyte count; or baPWV.

DISCUSSION
==========

In this double-blind, randomized, and placebo-controlled study, there was no significant improvement in metabolic parameters, oxidative or inflammatory markers, or baPWV after oral administration of KRG compared to the placebo group.

Central obesity is a core characteristic of metabolic syndrome. Increased visceral adipose tissues are accompanied by chronic low grade inflammation and insulin resistance, which explains various features of metabolic syndrome. Adipose tissue is now accepted as an endocrine organ that secretes a variety of adipokines and cytokines. Thus, metabolic syndrome is implicated by an increased production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor-α.[@B18],[@B19] These cytokines play a key role in regulating the vessel wall tone by affecting the release of nitric oxide and endothelin-1 in the subendothelial space.[@B20],[@B21] This cascade may cause endothelial dysfunction and alter arterial elastic properties, leading to increased blood pressure and structural stiffness. KRG has several constituents with curable properties, of which ginsenosides have been noticed to be a major pharmacologic component. In animal studies and an *in vitro* study using human umbilical vein endothelial cell,[@B22]-[@B24] ginsenosides relax blood vessels and improve blood flow through nitric oxide release by activating endothelial nitric oxide synthase. Human clinical trials have demonstrated that KRG has favorable effects on blood pressure, and the study included a range of subjects, from those in good health to patients with congestive heart failure, but the majority of patients did not demonstrate a significant change in response to KRG administration.[@B25] Han et al.[@B10] reported that red ginseng significantly decreased systolic blood pressure in essential hypertension patients without antihypertensive medication. Some studies have reported that ginseng slightly increased blood pressure,[@B9],[@B26] but the study was conducted in healthy subjects. Therefore, there was a possibility that KRG\'s effects vary according to baseline blood pressure. We excluded subjects who were currently taking drugs that could modify metabolic and vascular function parameters, and patients in need of medical treatment. This may have resulted in a study population with relatively early metabolic syndrome that attenuated the favorable effects of KRG.

KRG has also been reported to improve insulin resistance and have anti-hyperlipidemic effects.[@B7],[@B11],[@B27] Furthermore, some studies have indicated that KRG might reduce weight gain.[@B28],[@B29] Although the reason for favorable energy metabolism of KRG is unclear, it may be explained by activation of adenosine monophosphate-activated protein kinase[@B29] and reductions in food intake or appetite.[@B30] However, firm evidence is still lacking in clinical trials.[@B25]

The lack of beneficial effects for KRG in this study has several possible explanations. First, we could not fully control participants\' lifestyle such as exercise and diet. Although all participants were instructed to exercise on a regular basis and mildly reduce their calorie intake, each individual\'s compliance may have been different. Second, the relationship between KRG dosage and its effect on CVD risks was not evaluated. Further research is warranted to clarify the influence of a dose-effect relationship to determine the optimum dosage in subjects with metabolic syndrome. Third, the ginsenoside Rg3 has been known to improve insulin sensitivity,[@B31] but the 0.22% of Rg3 used in this study may be too low to be expected to have any beneficial effects on metabolic parameters. Lastly, gender differences were not considered. Further investigation is warranted to better understand gender differences in the cardiovascular effects of KRG in subjects with metabolic syndrome.

In conclusion, we found no evidence that KRG had an effect on blood pressure, lipid profile, oxidized LDL, fasting blood glucose, or arterial stiffness in subjects with metabolic syndrome. These findings warrant further longer-term prospective clinical investigations with a larger population.
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###### 

Clinical characteristics of the subjects at baseline.
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Values are presented as mean ± SD or number (%).

^\*^P-values were calculated with t-test or chi-square test. ^†^Alcohol drinking ≥ 140 g/wk. ^‡^Regular exercise ≥ twice/wk.

###### 

Changes in the laboratory values after the administration of the ginseng or placebo for 12 weeks.
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HDL: high density lipoprotein, LDL: low density lipoprotein, HOMA-IR: homeostasis model assessment for insulin resistance, WBC: white blood cell, baPWV: brachial-ankle pulse wave velocity.

^\*^Δ: change after 12 weeks. ^†^P-value was calculated by Wilcoxon signed-rank test for within-treatment differences. ^‡^P-value was calculated by Wilcoxon rank-sum test for between-treatment differences.
